瘢痕防治及其研究进展

doi:10.3877/cma.j.issn.1674-0785.2019.06.012

瘢痕是当前医学研究的重点领域之一，尤其是评价指标和防治手段已经受到越来越多的关注。瘢痕一般分为表浅性瘢痕、萎缩性瘢痕、增生性瘢痕和瘢痕疙瘩。其发生机制一般认为是皮肤创伤愈合过程中，由于各种因素导致的伤口中成纤维细胞异常增生、胶原合成分泌和降解失衡，最终形成伤口皮肤组织异常过度增生。瘢痕严重程度主要依靠温哥华瘢痕量表（VSS）、患者和观察者瘢痕评估量表（POSAS）进行评测。其治疗手段主要有压力疗法、硅凝胶疗法、放射疗法、激光疗法、激素注射疗法以及手术切除治疗等，目前认为多种疗法联合治疗仍是瘢痕防治安全、有效的策略。

关键词: 瘢痕, 增生性, 瘢痕疙瘩, 手术, 联合治疗

At present, scar is one of the key areas of medical research, and its evaluation, prevention, and control methods have received more and more attention. Scar is generally divided into superficial scar, atrophic scar, hypertrophic scar, and keloid. The mechanism is thought to involve abnormal proliferation of fibroblasts and imbalance of secretion, synthesis, and degradation of collagen caused by various factors during the skin wound healing process, which eventually result in the formation of abnormal hypertrophic skin tissue. The severity of scar is measured mainly using the Vancouver scar scale (VSS), the Patient and Observer scar Assessment scale (POSAS) and so on. Its main treatments include pressure therapy, silicone gel therapy, radiation therapy, laser therapy, intralesional corticosteroids, and surgical therapy. Now it is believed that combination therapy is still the safe and effective strategy for the prevention and control of scar.

Key words: Scar, Hyperplastic, Keloid, Surgery, Combined therapy

表1 温哥华瘢痕量表指标及评分标准

指标	0分	1分	2分	3分	4分	5分
色泽	正常	较浅	深浅混合	较深	?	?
厚度	正常	<1 mm	<1~2 mm	<2~4 mm	>4 mm	?
血管分布	正常	肤色粉红	肤色偏红	肤色为紫色	?	?
柔软度	正常	柔软（最少阻力下皮肤变性）	柔顺（压力下变性）	较硬（不能变形，对压力有阻力）	弯曲（组织如绳状）	挛缩（致残或扭曲）

表1 温哥华瘢痕量表指标及评分标准

指标	0分	1分	2分	3分	4分	5分
色泽	正常	较浅	深浅混合	较深	?	?
厚度	正常	<1 mm	<1~2 mm	<2~4 mm	>4 mm	?
血管分布	正常	肤色粉红	肤色偏红	肤色为紫色	?	?
柔软度	正常	柔软（最少阻力下皮肤变性）	柔顺（压力下变性）	较硬（不能变形，对压力有阻力）	弯曲（组织如绳状）	挛缩（致残或扭曲）

图1 增生性瘢痕防治方案流程

图2 瘢痕疙瘩防治方案流程

1	Lv K, Xia Z. Chinese expert consensus on clinical prevention and treatment of scar [J]. Burns Trauma, 2018, 17(6): 27.
2	Wiseman J, Simons M, Kimble R, et al. Effectiveness of topical silicone gel and pressure garment therapy for burn scar prevention and management in children: study protocol for a randomised controlled trial [J]. Trials, 2017, 18(1): 72.
3	Meaume S, Le Pillouer-Prost A, Richert B, et al. Management of scars: updated practical guidelines and use of silicones [J]. Eur J Dermatol, 2014, 24(4): 435-443.
4	Thompson CM, Sood RF, Honari S, et al. What score on the Vancouver Scar Scale constitutes a hypertrophic scar? Results from a survey of North American burn-care providers [J]. Burns, 2015, 41(7): 1442-1448.
5	van der Wal MB, Tuinebreijer WE, Bloemen MC, et al. Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scars [J]. Qual Life Res, 2012, 21(1): 13-23.
6	Fearmonti R, Bond J, Erdmann D, et al. A review of scar scales and scar measuring devices [J]. Eplasty, 2010, 21(10): e43.
7	Brusselaers N, Pirayesh A, Hoeksema H, et al. Burn scar assessment: a systematic review of different scar scales [J]. J Surg Res, 2010, 164(1): e115-e123.
8	Vercelli S, Ferriero G, Bravini E, et al. Cross-cultural adaptation, reproducibility and validation of the Italian version of the Patient and Observer Scar Assessment Scale (POSAS) [J]. Int Wound J, 2017, 14(6): 1262-1268.
9	Nedelec B, Shankowsky HA, Tredget EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume [J]. J Burn Care Rehabil, 2000, 21(3): 205-212.
10	Oliveira GV, Chinkes D, Mitchell C, et al. Objective assessment of burn scar vascularity, erythema, pliability, thickness, and planimetry [J]. Dermatol Surg, 2005, 31(1): 48-58.
11	Cheng W, Saing H, Zhou H, et al. Ultrasound assessment of scald scars in Asian children receiving pressure garment therapy [J]. J Pediatr Surg, 2001, 36(3): 466-469.
12	Corrado G, Calagna G, Cutillo G, et al. The Patient and Observer Scar Assessment Scale to Evaluate the Cosmetic Outcomes of the Robotic Single-Site Hysterectomy in Endometrial Cancer [J]. Int J Gynecol Cancer, 2017, 28(1): 194-199.
13	Ma X, Xia QJ, Li G, et al. Aesthetic principles access thyroidectomy produces the best cosmetic outcomes as assessed using the patient and observer scar assessment scale [J]. BMC Cancer, 2017, 17(1): 654.
14	Atiyeh BS, El KA, Dibo SA. Pressure garment therapy (PGT) of burn scars: evidence-based efficacy [J]. Ann Burns Fire Disasters, 2013, 26(4): 205-212.
15	Giele HP, Liddiard K, Currie K, et al. Direct measurement of cutaneous pressures generated by pressure garments [J]. Burns, 1997, 23(2): 137-141.
16	Artzi O. Treatment of scars in the 21st century [J]. Harefuah, 2016, 155(10): 618-621.
17	Forbat E, Ali FR, Al-Niaimi F. Treatment of keloid scars using light-, laser-and energy-based devices: a contemporary review of the literature [J]. Lasers Med Sci, 2017, 32(9): 2145-2154.
18	Karmisholt KE, Haerskjold A, Karlsmark T, et al. Early laser intervention to reduce scar formation - a systematic review [J]. J Eur Acad Dermatol Venereol, 2018, 32(7): 1099-1110.
19	Qu L, Liu A, Zhou L, et al. Clinical and molecular effects on mature burn scars after treatment with a fractional CO(2) laser [J]. Lasers Surg Med, 2012, 44(7): 517-524.
20	Waibel JS, Wulkan AJ, Rudnick A, et al. Treatment of Hypertrophic Scars Using Laser-Assisted Corticosteroid Versus Laser-Assisted 5-Fluorouracil Delivery [J]. Dermatol Surg, 2018, 45(3): 423-430.
21	Tawfik A, Osman MA, Rashwan I. A Novel Treatment of Acne Keloidalis Nuchae by Long-Pulsed Alexandrite Laser [J]. Dermatol Surg, 2018, 44(3): 413-420.
22	Polat M, Kaya H, Sahin A. A New Approach in the Treatment of Keloids: UVA-1 Laser [J]. Photomed Laser Surg, 2016, 34(3): 130-133.
23	Tziotzios C, Profyris C, Sterling J. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part II. Strategies to reduce scar formation after dermatologic procedures [J]. J Am Acad Dermatol, 2012, 66(1): 13-26.
24	Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature [J]. Arch Facial Plast Surg, 2006, 8(6): 362-368.
25	Har-Shai Y, Sabo E, Rohde E, et al. Intralesional cryosurgery enhances the involution of recalcitrant auricular keloids: a new clinical approach supported by experimental studies [J]. Wound Repair Regen, 2006, 14(1): 18-27.
26	Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management [J]. Aesthetic Plast Surg, 2008, 32(1): 82-92.
27	Mangano A. Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial--the pivotal role of statistics [J]. Plast Reconstr Surg, 2011, 128(2): 607.
28	van der Wal MB, van Zuijlen PP, van de Ven P, et al. Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial [J]. Plast Reconstr Surg, 2010, 126(2): 524-531.
29	Momeni M, Hafezi F, Rahbar H, et al. Effects of silicone gel on burn scars [J]. Burns, 2009, 35(1): 70-74.
30	Li Z, Jin Z. Comparative effect and safety of verapamil in keloid and hypertrophic scar treatment: a meta-analysis [J]. Ther Clin Risk Manag, 2016, 12: 1635-1641.
31	Hayashi T, Furukawa H, Oyama A, et al. A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision [J]. Dermatol Surg, 2012, 38(6): 893-897.
32	Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids [J]. Dermatol Surg, 2012, 38(1): 104-109.
33	Hatamipour E, Mehrabi S, Hatamipour M, et al. Effects of combined intralesional 5-Fluorouracil and topical silicone in prevention of keloids: a double blind randomized clinical trial study [J]. Acta Med Iran, 2011, 49(3): 127-130.
34	Aggarwal H, Saxena A, Lubana PS, et al. Treatment of keloids and hypertrophic scars using bleom [J]. J Cosmet Dermatol, 2008, 7(1): 43-49.
35	Seo SH, Sung HW. Treatment of keloids and hypertrophic scars using topical and intralesional mitomycin C [J]. J Eur Acad Dermatol Venereol, 2012, 26(5): 634-638.
36	Berman B, Harrison-Balestra C, Perez OA, et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study [J]. J Drugs Dermatol, 2009, 8(5): 455-458.
37	Chanprapaph K, Tanrattanakorn S, Wattanakrai P, et al. Effectiveness of onion extract gel on surgical scars in asians [J]. Dermatol Res Pract, 2012: 212945.
38	Viera MH, Amini S, Valins W, et al. Innovative therapies in the treatment of keloids and hypertrophic scars [J]. J Clin Aesthet Dermatol, 2010, 3(5): 20-26.
39	Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study [J]. Mayo Clin Proc, 2006, 81(8): 1023-1028.
40	Gauglitz GG, Bureik D, Dombrowski Y, et al. Botulinum toxin A for the treatment of keloids [J]. Skin Pharmacol Physiol, 2012, 25(6): 313-318.
41	Xiao Z, Qu G. Effects of botulinum toxin type a on collagen deposition in hypertrophic scars [J]. Molecules, 2012, 17(2): 2169-2177.
42	Del TD, Dedhia R, Tollefson TT. Advances in scar management: prevention and management of hypertrophic scars and keloids [J]. Curr Opin Otolaryngol Head Neck Surg, 2016, 24(4): 322-329.
43	Kim S, Choi TH, Liu W, et al. Update on scar management: guidelines for treating Asian patients [J]. Plast Reconstr Surg, 2013, 132(6): 1580-1589.
44	Wang LZ, Ding JP, Yang MY, et al. Treatment of facial post-burn hyperpigmentation using micro-plasma radiofrequency technology [J]. Lasers Med Sci, 2015, 30(1): 241-245.
45	Wang S, Mi J, Li Q, et al. Fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in Asians: A prospective study of 95 patients [J]. Lasers Surg Med, 2017, 49(6): 563-569.
46	Ding J, Chen B, Wu J, et al. Micro-plasma radio frequency treatment for facial post-burn hyperpigmentation [J]. Zhonghua Zheng Xing Wai Ke Za Zhi, 2014, 30(2): 99-101.
47	Wurzer P, Branski LK, Kamolz LP, et al. Fat and Adipose-Derived Stem Cell Grafts in Acute Burns [J]. J Burn Care Res, 2016, 37(3): e302.
48	Yao Y, Dong Z, Liao Y, et al. Adipose Extracellular Matrix/Stromal Vascular Fraction Gel: A Novel Adipose Tissue-Derived Injectable for Stem Cell Therapy [J]. Plast Reconstr Surg, 2017, 139(4): 867-879.
49	Kafka M, Collins V, Kamolz LP, et al. Evidence of invasive and noninvasive treatment modalities for hypertrophic scars: A systematic review [J]. Wound Repair Regen, 2017, 25(1): 139-144.

[1]	金鑫, 谢卯, 刘芸, 杨操, 杨述华, 许伟华. 个性化股骨导向器辅助初次全髋关节置换的随机对照研究[J]. 中华关节外科杂志(电子版), 2023, 17(06): 780-787.
[2]	邓华梅, 袁札根, 曾德荣, 潘珊珊, 张葆青, 欧爱华, 曹学伟. 全膝关节置换术中气压止血带应用效果与影响因素分析[J]. 中华关节外科杂志(电子版), 2023, 17(06): 788-794.
[3]	董红华, 郭艮春, 江磊, 吴雪飞, 马飞翔, 李海凤. 骨科康复一体化模式在踝关节骨折快速康复中的应用[J]. 中华关节外科杂志(电子版), 2023, 17(06): 802-807.
[4]	杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[5]	李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[6]	逄世江, 黄艳艳, 朱冠烈. 改良π形吻合在腹腔镜全胃切除消化道重建中的安全性和有效性研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 66-69.
[7]	杨体飞, 杨传虎, 陆振如. 改良无充气经腋窝入路全腔镜下甲状腺手术对喉返神经功能的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 74-77.
[8]	陈旭渊, 罗仕云, 李文忠, 李毅. 腺源性肛瘘经手术治疗后创面愈合困难的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 82-85.
[9]	纪凯伦, 郝少龙, 孙海涛, 韩威. 减重术后胆囊结石形成机制的新进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 100-103.
[10]	陈航, 闵翔. 日间甲状腺切除术后出血的12例临床分析及应对措施[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 600-602.
[11]	罗佳, 赵晶晶, 曹小珍, 钟玲, 范林军, 曾令娟. 单侧腋窝双侧乳晕入路机器人甲状腺术后局部加压预防皮下隧道出血的对照研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 603-606.
[12]	陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[13]	李博, 胡刚, 邱文龙, 汤坚强, 王锡山. 多功能吲哚菁绿近红外荧光血管成像技术在腹腔镜直肠癌经自然腔道取标本手术（NOSES Ⅳ式）中的应用（附视频）[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 524-528.
[14]	程相阵. 腹茧症9例诊治分析并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(9): 968-971.
[15]	李静, 张玲玲, 邢伟. 兴趣诱导理念用于小儿手术麻醉诱导前的价值及其对家属满意度的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 812-817.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Progress in scar prevention and treatment

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Progress in scar prevention and treatment